Disease overview (Classification of Acromegaly)
- Ø Approved and Emerging therapies (Pipeline assessment and key clinical trials profile)
- Ø Epidemiology (Incidence, prevalence, mortality and survival)
- Ø Market share and patient share uptake
- Ø KOL’s perspective on current treatment & unmet needs
- Ø Market and product event analysis
- Ø Market forecast 2020 - 2030 (11 years of future market projections)
Report Summary
Thelansis “Acromegaly - Market
outlook, Epidemiology, Market Forecast and Competitive Land- scape - 2020 To
2030 ” this report provides a
comprehensive study of the disease area land- scape and changing market dynamics
with respect to the cur- rent &
future market events for the 8 MM countries (USA, EU5, Japan & China).
Report Overview
The report provides a comprehensive view of disease events, classification,
identified and emerging, Clinical Manifestations, progression, signs &
symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at
country level
View Report: Acromegaly – Market outlook, Epidemiology,
Market Forecast and Competitive Landscape Report – 2019 To 2030
Acromegaly
Market Comprehensive insight on patient segmentation based on Origin (Pituitary Tumor
& Non-Pituitary Tumor), Adenoma size (Macroadenomas and
Microadenomas), responsive to
treatment (Surgical & Non-surgical), Clinical Manifestations (osteoarticular
manifestation, cardiovascular manifestation, respiratory manifestation,
gastrointestinal manifestation, endocrinological and other manifestations) has been provided into the epidemiology
(Incidence and Prevalence) section of the
Acromegaly and its treatment in the 8 MM
countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK),
Japan, and China
Drug utilization and analysis on the current clinical
practice, KOL perspective on upcoming therapies, estimated TPP for pipeline as-
sets, clinical characteristics upcoming therapies and future treatment paradigm.
Market aggregation on newly diagnosed patient pool,
Thelansis estimation on persistence, compliance, adherence and a historic view
of changing market dynamics and product-level patient flow of Acromegaly
in the 8 MM Countries for the period 2020 – 2030.
Forecast Model – Snapshot
Epidemiology
Disease Overview
Acromegaly is a hormonal disorder that results from the
availability of too much growth hormone (GH) in the body. The pituitary, a
small gland in the brain, makes GH. In acromegaly, the pituitary produces
excessive amounts of GH. Usually, the excess GH comes from benign, or noncancerous,
tumors on the pituitary. These benign tumors are called Adenomas.
Competitive Landscape
Acromegaly Market
Scenario:
There are three dimension treatment pattern are being
under practice such as; surgery, medical therapy and radiotherapy. Pituitary
surgery is recommended as the primary treatment in patients with microadenomas
and in patients with macroadenomas that are associated with local mass effects
or are enclosed and potentially curable surgically because surgery can lead to
durable control of the tumor mass and associated biochemical effects.
Acromegaly Market Forecast
Thelansis’
research team expects the Acromegaly market potential for 2030 at $X.XXB in 8MM
countries. Out of this market, 52.5% sales are expected to be contributed from
the US market whereas XX.X% is expected to come from EU-5. Japan and China are
expected to contribute XX.X% and X.X% respectively.
Acromegaly Products Pricing Scenario:
Upcoming
therapy probably transform the treatment paradigm of Acromegaly in the near
future. Clinical trials some level of promising results like proportion of
patients maintaining their baseline and in most of the patients, without
causing significant safety concerns. Of course, some questions about targeted
therapy still remain un- solved.
Based on the KOL Insights gathered from Primary Market Research (PMR) of Acromegaly market Thelansis expects upcoming
therapies may raise significant concerns with respect to the treatment cost as
much as USD 85,000 to USD 124,000 per patient. To control the cost research
have developed algorithm for tiered testing guide to enhance the clinical
diagnosis of Acromegaly, in the other hand it is hard to distinguish genetic
variations such as pin- pointing the phenotype and exact biomarker.
Contact Us
About Thelansis: - As the name depicts Thelansis is specialized in “Therapy
Area Landscape
Analy- sis” along with market
intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies
to successfully prepare, launch, and commercialize their products. Our
Syndicated research reports
include Market Insight,
Pipeline Insight, Product
Insight, Specialized Reports, Indication Outlook and Market
Access Reports. Our focused therapeutic approach provides our clients with
clinical and disease area expertise from an integrated team of academic,
medical, and industry specialists of our panel, Ask for our report offerings,
and Indication specific sample pages by sharing your email ID with us at,
p.potdar@thelansis.com
Peeyush Potdar
Delivery Head:
Email: p.potdar@thelansis.com
Visit us at
http://www.thelansis.com/
Delivery office
B-1030, C
Wing
Vrindavan
tech village Marathahalli
Outer ring
road, Bangalore- 560037
Sales office
183-Asylum
Street Hartfort, CT-06103, USA
Telephone
USA +1-302-380-3552 India +91-9899921259
Email
No comments:
Post a Comment